Response
We have read the comments of Dr Dziedzic et al with great interest. They are right that the elevation of interleukin-6 (IL-6) in acute stroke patients compared with healthy controls could be due to the cerebral ischemia or to the preexisting vascular pathology. However, Beamer and colleagues have already shown that IL-6 serum concentrations decline over 1 year after the event. 1 This strongly argues for an elevation of IL-6 levels by the acute stroke as we cannot assume the underlying atherosclerosis to regress. Nevertheless, vascular risk factors are likely to contribute also to the observed elevation of IL-6 levels in acute stroke patients.
The source of IL-6 in serum after stroke is another important issue. As IL-6 is ubiquitously expressed, we fully agree with Dziedzic et al that a nonneural source of IL-6 after stroke is conceivable. Unfortunately, there are no means to determine the origin of IL-6 in human stroke. The suggestion that serum IL-6 reflects, at least partly, IL-6 production of the ischemic brain is based on the following evidence: (1) Several studies have reported a tight correlation between stroke volume and IL-6 serum levels. [2] [3] [4] (2) In animal models of stroke there is a profound increase of IL-6 expression in neural cells. 5, 6 (3) Tarkowski and colleagues have found a higher rise of IL-6 in cerebrospinal fluid than in serum after stroke. 7 It is no contradiction that in the experimental study of Clark et al, serum levels of IL-6 had a marked increase by 3 hours, whereas IL-6 mRNA accumulation in the mouse brain (assessed by a single measurement of pooled samples) was not elevated until 12 hours. 8 The fact that Clark et al missed an earlier induction of IL-6 in the brain is due to the lack of statistical analysis since other studies have shown that IL-6 in the brain is significantly upregulated after only 2 hours of focal cerebral ischemia. 6 
